Eligibility for treatment with omalizumab in Italy and Germany

Respiratory Medicine

Volumn 108, Issue 1, 2014, Pages 50-56

  Buhl, Roland ^a   Marco, Andrea Gili ^b   Cohen, Daniel ^b   Canonica, Giorgio Walter ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergic asthma; Anti immunoglobulin E; Eligibility; Epidemiology

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING BETA2 AGONIST; OMALIZUMAB; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; DISEASE EXACERBATION; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; GENERAL PRACTITIONER; GERMANY; HUMAN; INTERVIEW; ITALY; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; PRIORITY JOURNAL; RESPIRATORY SPECIALIST;

ALLERGIC ASTHMA; ANTI-IMMUNOGLOBULIN E; ELIGIBILITY; EPIDEMIOLOGY;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELIGIBILITY DETERMINATION; GERMANY; HUMANS; IMMUNOGLOBULIN E; ITALY; PATIENT SELECTION; PREVALENCE; QUALITY OF LIFE; SAMPLING STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84893678640     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.10.026     Document Type: Article

References (23)

1. D. Price The use of omalizumab in asthma Prim Care Respir J 17 2008 62 72
2. M. Masoli, D. Fabian, S. Holt, and R. Beasley The global burden of asthma: executive summary of the GINA dissemination committee report Allergy 59 2004 469 478
3. K.F. Rabe, M. Adachi, C.K. Lai, J.B. Soriano, P.A. Vermeire, and K.B. Weiss et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys J Allergy Clin Immunol 114 2004 40 47
4. S.P. Peters, G. Ferguson, Y. Deniz, and C. Reisner Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment Respir Med 100 2006 1139 1151
5. L. Cazzoletti, A. Marcon, A. Corsico, C. Janson, D. Jarvis, and I. Pin et al. Asthma severity according to Global Initiative for Asthma and its determinants: an international study Int Arch Allergy Immunol 151 2010 70 79
6. European Medicines Evaluation Agency. Omalizumab (Xolair) summary of product characteristics. www.ema.europa.eu.
7. J. Bousquet, P. Cabrera, N. Berkman, R. Buhl, S. Holgate, and S. Wenzel et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma Allergy 60 2005 302 308
8. W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, and G.D. Cioppa et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
9. J. Corren, T.B. Casale, B. Lanier, R. Buhl, S. Holgate, and P. Jimenez Safety and tolerability of omalizumab Clin Exp Allergy 39 2009 788 797
10. S.T. Holgate, A.G. Chuchalin, J. Hebert, J. Lötvall, G.B. Persson, and K.F. Chung et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
11. M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hebert, and J. Bousquet et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
12. R. Niven, K.F. Chung, Z. Panahloo, M. Blogg, and G. Ayre Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study Respir Med 102 2008 1371 1378
13. W. Busse, R. Buhl, V.C. Fernandez, M. Blogg, J. Zhu, and M.D. Eisner et al. Omalizumab and the risk of malignancy: results from a pooled analysis J Allergy Clin Immunol 129 2012 983 989
14. S. Accordini, A. Corsico, I. Cerveri, D. Gislason, A. Gulsvik, and C. Janson et al. The socio-economic burden of asthma is substantial in Europe Allergy 63 2008 116 124
15. L. Cazzoletti, A. Marcon, C. Janson, A. Corsico, D. Jarvis, and I. Pin et al. Asthma control in Europe: a real-world evaluation based on an international population-based study J Allergy Clin Immunol 120 2007 1360 1367
16. Global Initiative for Chronic Asthma (GINA) Global strategy for asthma management and prevention December 2011 www.ginasthma.org
17. E.J. Sims, D. Price, J. Haughney, D. Ryan, and M. Thomas Current control and future risk in asthma management Allergy Asthma Immunol Res 3 2011 217 225
18. F. van Nooten, S. Stern, G.J. Braunstahl, C. Thompson, M. Groot, and R.E. Brown Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands J Med Econ 16 2013 342 348
19. R. Brown, F. Turk, P. Dale, and J. Bousquet Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma Allergy 62 2007 149 153
20. R.W. Dal Negro, S. Tognella, and L. Pradelli A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy J Asthma 49 2012 843 848
21. F. Menzella, N. Facciolongo, R. Piro, D. Formisano, A. Roggeri, and A. Simonazzi et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up Ther Adv Respir Dis 6 2012 87 95
22. S. Dewilde, F. Turk, M. Tambour, and T. Sandstrom The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden Curr Med Res Opin 22 2006 1765 1776
23. Y. Oba, and G.A. Salzman Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma J Allergy Clin Immunol 114 2004 265 269